Capital Cell

The Welcome Meet session in English is now open for registrations! This is a great opportunity to connect and learn more about Capital Cell’s unique investment proposition. Don’t miss out—secure your spot today: https://lu.ma/xk0im3xr

Hemerion Therapeutics' round is advancing at a great pace. And with reason: - groundbreaking technology, alreadu in clinical trials with patients in the USA - support from funds such as CAPTECH Santé - just announced an investment of 1 million euro from two funds - if you're a french tax resident, get 50% of your investment back under the #JEI tax break Round still open - don't miss it: https://lnkd.in/dyBSg93p

Cresce la rete di partner del Distretto Campania Bioscience! Dopo le collaborazioni avviate con Florida High Tech Corridor e Research Triangle Regional Partnership (RTRP) del North Carolina, siamo felici di annunciare di aver ampliato il nostro network con player internazionali di grande esperienza e rilevanza in ambito life sciences e non solo Un’occasione di crescita per tutte le nostre associate! Diamo il benvenuto a HealthTech Investor Summit, Capital Cell e BIND - Basque Open Innovation Platform *** The Distretto Campania Bioscience's network of partners is growing! After the collaborations started with the Florida High Tech Corridor and the Research Triangle Regional Partnership (RTRP) of North Carolina, we are happy to announce that we have expanded our network with international players of great experience and relevance in the life sciences sector and beyond An opportunity for growth for all our associates! We welcome HealthTech Investor Summit, Capital Cell, and BIND - Basque Open Innovation Platform

Pharmamel está haciendo grandes avances en su camino hacia el mercado farmacéutico y bursátil hacia BME | Bolsas y Mercados Españoles, con más de 214 inversores y 1.100.000 euros ya asegurados en la ronda de ampliación de capital Pre-IPO que estamos desarrollando a través de Capital Cell. Estamos más cerca que nunca de llevar nuestro innovador tratamiento intravenoso para la #sepsis a la práctica clínica. ¡Un momento clave para cualquier inversor interesado en formar parte de este proyecto con un impacto global! 🔵 Más detalles y la oportunidad de inversión aquí: 👉 📈 https://lnkd.in/dsy9Gu8m 🔵 últimas noticias publicadas aquí: https:👉📰 //https://lnkd.in/dqW_jPkC 📈 a-pre-ipo-avanza-farmaco-sepsis/20240830131216834850.html -- -- Pharmamel is making significant progress on its path towards the pharmaceutical market and the stock exchange with BME | Bolsas y Mercados Españoles , with more than 214 investors and €1,100,000 already secured in the Pre-IPO capital increase round we are conducting through Capital Cell. We are closer than ever to bringing our innovative intravenous treatment for #sepsis to clinical practice. A key moment for any investor interested in being part of this project with global impact! 🔵 More details and investment opportunity here: 👉 📈 https://lnkd.in/dDSyp_NC 🔵 Latest news published here: 👉📰 https://lnkd.in/dwG_44nK

🌞 La fin des vacances, c'est le retour au travail... et à l'investissement ! Pendant que vous profitiez de vos dernières baignades, chez MSInsight, on n'a pas chômé ! Avec 120 investisseurs déjà onboard et 84% de notre objectif atteint, notre campagne de crowdfunding sur Capital Cell avance à grands pas. Mais il reste encore du temps pour rejoindre l'aventure avant le 25 septembre ! Découvrez l'interview entre Luc Marchand, investisseur de la première heure, et Marc BESSOLES d'Apeiron Health Tech Consulting, qui représente Capital Cell en France et en Belgique. Cette discussion vous dévoilera tout sur MSInsight et notre mission. 🎥 https://lnkd.in/dhymJy8A Vous souhaitez nous rejoindre ? Rendez-vous sur notre page de crowdfunding ici pour en savoir plus et investir dès aujourd'hui ! 💶 https://lnkd.in/d9aBcVPi #RetourAuTravail #Investissement #MSInsight #CapitalCell #Innovation #AperionHealthTech

🔬 MSInsight : une révolution dans le diagnostic du cancer Dans le domaine complexe du diagnostic du cancer, MSInsight se distingue avec MSIcare, un outil innovant pour détecter l'Instabilité des Microsatellites (MSI), un biomarqueur crucial pour prédire la réponse à l'immunothérapie. Ce webinaire DealÜp a été l'occasion de découvrir cette technologie de pointe, rencontrer l'équipe et comprendre son impact potentiel sur le traitement du cancer. Un grand merci à Capital Cell pour l'organisation de ce webinaire instructif ! 📺 https://lnkd.in/gvkUp4qT Chez MSInsight, il ne reste plus qu'un mois pour soutenir notre campagne de financement participatif sur Capital Cell. Votre soutien est essentiel pour nous aider à déployer MSIcare et révolutionner les diagnostics du cancer à l'échelle mondiale. Rejoignez-nous dans cette aventure pour transformer les soins contre le cancer ! https://lnkd.in/d9aBcVPi #Cancer #Diagnostic #Innovation #MSInsight #CapitalCell

New investment opportunity on Capital Cell: OxyPrem AG launches a €2.3M funding round for the commercial launch of its second-generation sensors, OxyPrem NOAH, specifically designed for premature babies to provide real-time, high-precision detection of oxygen imbalances. 🧠 Current oxygen monitoring methods aren't designed for premature babies, often lacking in quality and accuracy. This poses a high risk of permanent brain damage from insufficient or excess oxygen. 🌍 High Demand: 1 in every 10 births is premature, and the specialized monitoring market is growing at a rate of 8% per year. 🎯 High Precision: OxyPrem's technology has demonstrated a reduction in false positives and negatives from 17% to 0.5%. 📊 Scientific Support: 13 clinical trials and 17 publications validate its effectiveness. 💡 Clinically Tested: OxyPrem 1.4, the company’s first product, has been used on more than 300 premature babies in 38 neonatal intensive care units (NICUs). 🔐 Intellectual Property: Protection until 2038, with 3 patents granted and 8 patents pending. 🚀 Expansion Potential: Future applications for other indications and additional adult markets. Led by Alexander Nitsch, Stefan Kleiser, and Dr. Daniel Ostojic, OxyPrem's technology offers a specialized solution for perinatal oxygen level monitoring, providing the quality and accuracy specifically designed for the unique needs of premature babies. https://lnkd.in/d5573y5j

Motivos para invertir en Biointaxis y la primera #TerapiaGénica 🧬 para curar la #AtaxiaDeFriedreich que ha demostrado datos preclínicos sobresalientes: https://lnkd.in/dmrCpUYc 👉 Si quieres participar en el #crowdfunding, a partir de 500 €, puedes hacerlo a través de la plataforma Capital Cell: https://lnkd.in/dvKbCiKZ #StopAtaxia #EnfermedadesRaras #neurología #TerapiasAvanzadas #biotecnología #salud

Motivos para invertir en Biointaxis y la primera #TerapiaGénica 🧬 para curar la #AtaxiaDeFriedreich que ha demostrado datos preclínicos sobresalientes: https://lnkd.in/dmrCpUYc 👉 Si quieres participar en el #crowdfunding, a partir de 500 €, puedes hacerlo a través de la plataforma Capital Cell: https://lnkd.in/dvKbCiKZ #StopAtaxia #EnfermedadesRaras #neurología #TerapiasAvanzadas #biotecnología #salud

〰 The genomics industry has been buzzing with significant investment activity and strategic acquisitions in recent months. Here's a snapshot of some of the key developments: 1️⃣ Illumina acquires Fluent BioSciences Inc. to accelerate single-cell analysis and discovery to a broader customer base / July 2024 https://lnkd.in/eFimbEhJ 2️⃣ Tempus AI Raises $410.7 Million in IPO / June 2024 https://lnkd.in/dHjTH_c5 3️⃣ Element Biosciences Raises Over $277 Million to Develop and Commercialize Sequencing and multi-omics technologies // july 2024 https://lnkd.in/eSHR6zgZ 4️⃣ Illumina completes the divestiture of GRAIL • GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25 https://lnkd.in/dY2nsdNQ ❗ KEEP THE INDUSTRY BUZZIN' ❗ Invest in MSInsight and become a stakeholder through Capital Cell. With 115 investors and 83% of our goal completed, you can contribute to transforming cancer care with genomics! ➡ https://lnkd.in/d9aBcVPi 🔍Takeaway: The clinical genomics market is more dynamic than ever, with substantial investments and strategic moves paving the way for groundbreaking advancements. The future looks incredibly promising!